Table 1.
Drug susceptibility of Leishmania donovani clinical isolates following Miltefosine treatment in cases of Visceral Leishmaniasis and Post kala-azar dermal Leishmaniasis.
Figure 1.
In vitro miltefosine susceptibility of parasite isolates from VL and PKDL cases before and after Mil treatment.
Sensitivity of VL and PKDL isolates at intracellular amastigote stage were determined by infection in murine macrophage cell line J774A.1. Each individual value represents mean IC50±SD of the results from two separate assays.
Figure 2.
PMM susceptibility profile of VL and PKDL isolates exposed or non-exposed to MIL treatment.
Susceptibility of VL and PKDL isolates at intracellular amastigote stage was determined by infection in murine macrophage cell line J774A.1. Each individual value represents mean IC50±SD of the results from two separate assays.
Figure 3.
Expression of LdMT and LdRos3 in clinical isolates of VL and PKDL.
Real-time reverse-transcription PCR expression analysis of L. donovani MIL transporter genes (LdMT and LdRos3) was performed using GAPDH as internal control. Graph shows the expression index, defined as ratio of gene expression relative to that of strain LdAG83. Data represent the mean±SD of the results of three independent experiments.